Peg-asparaginase for acute lymphoblastic leukemia (Q37719558)

22 August 2017

1 reference

title

Peg-asparaginase for acute lymphoblastic leukemia (English)

1 reference

22 August 2017

1 reference

Michael Rytting

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Expert Opinion on Biological Therapy

22 August 2017

published in

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

833-839

1 reference

Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

High-dose methotrexate and asparaginase for the treatment of children with acute lymphoblastic leukemia: why and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

Pegaspargase: a review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003769808

10.1517/14712591003769808

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference